Recursion Pharmaceuticals, Inc. Board of Directors

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Dr. Christopher C. Gibson Ph.D.

Dr. Christopher C. Gibson Ph.D.

Co-Founder, CEO & Director

Ms. Kristen Rushton M.B.A.

Ms. Kristen Rushton M.B.A.

Chief Operating Officer

Kevin Leggat

Kevin Leggat

Vice President of Finance & Accounting

Dr. Dean Y. Li M.D., Ph.D.

Dr. Dean Y. Li M.D., Ph.D.

Co-Founder & Independent Director

Mr. Jared Allenbach

Mr. Jared Allenbach

Senior Director of Investor Relations

Dr. David Hallett Ph.D.

Dr. David Hallett Ph.D.

Chief Scientific Officer

Mr. Ben R. Taylor

Mr. Ben R. Taylor

CFO & President of Recursion UK

Mr. Benjamin Mabey M.S.

Mr. Benjamin Mabey M.S.

Chief Technology Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.